Compare XFOR & SORNU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFOR | SORNU |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 313.1M |
| IPO Year | N/A | 2026 |
| Metric | XFOR | SORNU |
|---|---|---|
| Price | $3.56 | $9.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $28.50 | N/A |
| AVG Volume (30 Days) | ★ 420.2K | N/A |
| Earning Date | 03-24-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,979,000.00 | N/A |
| Revenue This Year | $1,266.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2925.74 | N/A |
| 52 Week Low | $1.35 | N/A |
| 52 Week High | $17.96 | N/A |
| Indicator | XFOR | SORNU |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 59.60 |
| Support Level | $3.52 | $9.98 |
| Resistance Level | $3.74 | $10.00 |
| Average True Range (ATR) | 0.18 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 7.56 | 80.00 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Soren Acquisition Corp is a blank check company.